1. Search Result
Search Result
Pathways Recommended: MAPK/ERK Pathway
Results for "

pathway

" in MedChemExpress (MCE) Product Catalog:

3822

Inhibitors & Agonists

73

Screening Libraries

19

Fluorescent Dye

73

Biochemical Assay Reagents

199

Peptides

2

MCE Kits

87

Inhibitory Antibodies

1147

Natural
Products

15

Recombinant Proteins

274

Isotope-Labeled Compounds

2

Antibodies

13

Click Chemistry

44

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-107551

    Hedgehog Gli Cancer
    Hh Pathway-IN-1, a Hedgehog (Hh) pathway inhibitor, is a potent Gli antagonist. Hh Pathway-IN-1 inhibits Hh pathway functional with an IC50 value of 1.1 µM in C3H10T1/2 cells. Hh Pathway-IN-1 does not inhibit Wnt signaling. Hh Pathway-IN-1 shows anti-proliferative activity. Hh Pathway-IN-1 decreases the GLI1 mRNA expression. Hh Pathway-IN-1 inhibits colony formation in a dose-dependent manner .
    Hh Pathway-IN-1
  • HY-153750

    Wnt Cancer
    Wnt pathway inhibitor 3 is a potent wnt inhibitor with an IC50 value of 45 nM. Wnt pathway inhibitor 3 shows antiproliferative activity .
    Wnt pathway inhibitor 3
  • HY-136073

    Wnt Cancer
    Wnt pathway activator 2 (compound 2) is a potent Wnt activator with an EC50 of 13 nM .
    Wnt pathway activator 2
  • HY-153753

    Wnt Cancer
    Wnt pathway inhibitor 4 (compound 16D) is an anticancer agent that has anti-proliferative activity .
    Wnt pathway inhibitor 4
  • HY-136541
    YB-0158
    2 Publications Verification

    Wnt pathway inhibitor 2

    Wnt Apoptosis Cancer
    YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .
    YB-0158
  • HY-B1899A
    Taurodeoxycholic acid sodium hydrate
    3 Publications Verification

    Sodium taurodeoxycholate monohydrate

    G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Metabolic Disease
    Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway .
    Taurodeoxycholic acid sodium hydrate
  • HY-P99965

    SKY59; RO7112689; RG-6107

    Complement System Cardiovascular Disease Metabolic Disease
    Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
    Crovalimab
  • HY-129426

    Akt Cancer
    PDK1/Akt/Flt dual pathway inhibitor is one of a component of KP372-1 (HY-15673 ), and inhibits PDK1/Akt/Flt dual pathway .
    PDK1/Akt/Flt dual pathway inhibitor
  • HY-169730

    Wnt Cancer
    Wnt pathway inhibitor 5 (Compound 28) is wnt pathway inhibitor, with an IC50 value of < 0.003 μΜ. Wnt pathway inhibitor 5 inhibits many cancers, including ovarian teratocarcinoma cancer, breast cancer, osteosarcoma, head and neck squamous carcinoma .
    Wnt pathway inhibitor 5
  • HY-W089835R

    Reference Standards G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Metabolic Disease
    Sodium taurodeoxycholate hydrate (Standard) is the analytical standard of Sodium taurodeoxycholate hydrate. This product is intended for research and analytical applications. Sodium taurodeoxycholate hydrate, a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Sodium taurodeoxycholate hydrate activates the S1PR2 pathway in addition to the TGR5 pathway .
    Sodium taurodeoxycholate hydrate (Standard)
  • HY-Y0641
    3-Phenoxybenzaldehyde
    1 Publications Verification

    m-Phenoxybenzaldehyde

    Complement System Inflammation/Immunology
    3-Phenoxybenzaldehyde has weak complement classical pathway inhibition and hemolytic activity .
    3-Phenoxybenzaldehyde
  • HY-N9474

    5-Diphosphomevalonic acid tetralithium; Mevalonic acid 5-diphosphate tetralithium

    Endogenous Metabolite Others
    Mevalonic acid 5-pyrophosphate (5-Diphosphomevalonic acid) tetralithium is an endogenous metabolite of the mevalonate pathway .
    Mevalonic acid 5-pyrophosphate tetralithium
  • HY-12848C
    SAG dihydrochloride
    30+ Cited Publications

    Smo Cancer
    SAG dihydrochloride is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG dihydrochloride activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
    SAG dihydrochloride
  • HY-N1930

    Hinesol

    Apoptosis Cancer
    (-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer .
    (-)-Hinesol
  • HY-W777433

    Endogenous Metabolite Infection Others
    Cyclobenzaprine b-D-glucuronide is a metabolite of Cyclobenzaprine. Cyclobenzaprine b-D-glucuronide can be used to treat diseases associated with coronavirus infection. Cyclobenzaprine b-D-glucuronide can be used to study the metabolic pathways of Cyclobenzaprine in the body and as a potential candidate for studying coronavirus treatment .
    Cyclobenzaprine b-D-glucuronide
  • HY-155646

    NF-κB Inflammation/Immunology
    Anti-inflammatory agent 48 is an anti-inflammatory agent based on its role in inhibiting the NF-κB signaling pathway and activating HO-1 expression .
    Anti-inflammatory agent 48
  • HY-153456

    Hedgehog Cancer
    Hedgehog IN-2 (Compound 20) is an inhibitor of Hedgehog pathway with an IC50 value less than 0.003 μM in C3H10T1/2 cells .
    Hedgehog IN-2
  • HY-W400421

    3-Hydroxy VPA

    Endogenous Metabolite Metabolic Disease
    3-Hydroxyvalproic acid (3-Hydroxy VPA) is a metabolite of valproic acid. 3-Hydroxyvalproic acid is a weak inhibitor of enzymes related to the mitochondrial β-oxidation pathway. 3-Hydroxyvalproic acid is promising for research of diseases related to abnormal valproic acid metabolism .
    3-Hydroxyvalproic acid
  • HY-147789

    Akt Neurological Disease Cancer
    FPDT is an anti-glioblastoma agent. FPDT displays the IC50 value of 45–68 μM for GBM cells and >100 μM for astrocytes. Anti-glioblastoma activity of FPDT is linked to downregulation of the AKT pathway .
    FPDT
  • HY-15398C

    Epicholecalciferol

    Hedgehog Cancer
    3-epi-Vitamin D3 (Epicholecalciferol) (Compound 4), a Vitamin D3 analogue, is a Hedgehog pathway inhibitor with an IC50 of 39.2 μM measured in U87MG cells .
    3-epi-Vitamin D3
  • HY-19542
    C6 Ceramide
    3 Publications Verification

    C6-Cer; N-Hexanoylsphingosine

    Apoptosis Cancer
    C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
    C6 Ceramide
  • HY-174321

    p38 MAPK PI3K Akt NF-κB Cancer
    A2073 is a flavagline derivative that potently inhibits the proliferation of erythroleukemia cells by causing cell cycle arrest and suppressing the MAPK, NF-κB, and PI3K signaling pathways. A2073 formes stable interactions with cell cycle-related proteins (CDK1, CCNA2, PRIM1). A2073 exhibits significant anti-proliferative activity against tumor cells while maintaining a favorable toxicity profile in a zebrafish xenograft tumor model. A2073 can be used for the study of acute erythroleukemia.
    A2073
  • HY-P990025

    ARGX-117

    Complement System Inflammation/Immunology
    Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
    Empasiprubart
  • HY-171115

    GPR84 Aldose Reductase Metabolic Disease
    Pyrone-211 is a potent GPR84 agonist and AKR1C3 inhibitor. Pyrone-211 participates in an expanded polyamine pathway .
    Pyrone-211
  • HY-135282

    Dihydroorotate Dehydrogenase DNA/RNA Synthesis Infection
    DHODH-IN-1 (compound 18d) is a potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC50 of 25 nM. DHODH-IN-1 is an inhibitor of pyrimidine biosynthesis pathway .
    DHODH-IN-1
  • HY-135516
    Dalosirvat
    2 Publications Verification

    SM-04554; Wnt pathway activator 1

    Wnt Cancer
    Dalosirvat (SM-04554) is a potent Wnt activator extracted from patent WO2012024404A1, compound 1, has an EC50s of 28-29 nM .
    Dalosirvat
  • HY-156814

    Hedgehog Cancer
    HPP-9 is a Proteolysis-Targeting Chimeras (PROTACs) based on Hedgehog Pathway Inhibitor-1 (HPI-1), with the pIC50 of 6.71, that can degrade BET bromodomains. HPP-9 has antitumor activity [1[.
    HPP-9
  • HY-W738465

    N-Carbonylguanidine

    Endogenous Metabolite Metabolic Disease
    N,N-Dimethylamidino Urea (N-Carbonylguanidine) is an intermediate in the electrochemical oxidation of Metformin (HY-B0627). Metformin can be used in the study of type 2 diabetes. N,N-Dimethylamidino Urea can be used as a marker to study the metabolic pathway of metformin in vivo .
    N,N-Dimethylamidino Urea
  • HY-169126

    β-catenin Wnt Cancer
    β-catenin modulator IIa-661 is a β-catenin modulator that modulates β-catenin activity and inhibits the activity of the Wnt/wingless (wg) signaling pathway. β-catenin modulator IIa-661 can be utilized in cancer research .
    β-catenin modulator IIa-661
  • HY-W011474

    NF-κB Inflammation/Immunology
    Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model .
    Geranylgeraniol
  • HY-178711

    Others Metabolic Disease
    18-Oxooctadecanoic acid is a long-chain fatty acid derivative. 18-Oxooctadecanoic acid is exclusively oxidized by P450BM-3 to the corresponding α,ω-dicarboxylic acid (1,18-octadecanedioic acid) without undergoing decarboxylation to form one-carbon-shorter olefins. 18-Oxooctadecanoic acid can be used for the study of metabolic pathways of aldehyde-containing long-chain fatty acids .
    18-Oxooctadecanoic acid
  • HY-146757

    RIP kinase Inflammation/Immunology
    RIPK1-IN-13 (Compound 8) is a potent inhibitor of RIPK1 with an IC50 value of 1139 nM. RIPK1-IN-13 blocks the activation of the necroptosis pathway via the inhibition of RIPK1. RIPK1-IN-13 has the potential for the research of inflammation diseases .
    RIPK1-IN-13
  • HY-117229

    Drug Metabolite Cancer
    Sonidegib metabolite M48 is the main circulating metabolite of Sonidegib. Sonidegib is a hedgehog pathway inhibitor. M48 showed a much longer Tmax (60 h) than Sonidegib .
    Sonidegib metabolite M48
  • HY-W097899
    Vanillylamine
    1 Publications Verification

    JNK Cancer
    Vanillylamine is an immediate precursor for capsaicinoids. Vanillylamine is a derivative of Vanillin (HY-N0098) is synthesized through a transaminase reaction in the phenylpropanoid pathway of capsaicinoid synthesis. Vanillylamine significantly alleviates myelosuppression caused by abdominal and pelvic tumor chemotherapy .
    Vanillylamine
  • HY-W097899R

    JNK Cancer
    Vanillylamine is an immediate precursor for capsaicinoids. Vanillylamine is a derivative of Vanillin (HY-N0098) is synthesized through a transaminase reaction in the phenylpropanoid pathway of capsaicinoid synthesis. Vanillylamine significantly alleviates myelosuppression caused by abdominal and pelvic tumor chemotherapy .
    Vanillylamine (Standard)
  • HY-164145

    TGF-β Receptor Others Cancer
    CDD-1653 is a potent and selective BMPR2 inhibitor (IC50=2.8 nM). CDD-1653 reduces the ability of ATP to bind to the kinase domain of BMPR2, thereby affecting the phosphorylation of SMAD1/5/8 transcription factors, which play a key role in the BMP signaling pathway. CDD-1653 can be used to study diseases related to the BMP signaling pathway .
    CDD-1653
  • HY-108516

    Wnt PARP Cancer
    TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with Kds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC50s of 0.709 μM and 0.215 μM, respectively .
    TC-E 5001
  • HY-147897

    Apoptosis Cancer
    Apoptosis inducer 9 induces apoptosis with IC50 value of 4.21 μM. Apoptosis inducer 9 induces apoptosis through the mitochondrial pathway and enhance the expression of Cl-caspase-3, Cl-caspase-9 and Cl-PARP. Apoptosis inducer 9 can be used the potential to develop new anti-proliferative agents .
    Apoptosis inducer 9
  • HY-172747

    PARP Cancer
    TNKS-2-IN-3 (Compound 5) is a selective competitive tankyrase 2 (TNKS2) inhibitor with an IC50 value of 0.3 nM, showing over 20-fold selectivity over TNKS1 and more than 100-fold selectivity over PARP1/2. TNKS-2-IN-3 stabilizes axin and suppresses the Wnt/β-catenin pathway by inhibiting TNKS2-mediated ADP-ribosylation, exhibiting antiproliferative activity in colorectal cancer cells. TNKS-2-IN-3 is proming for rasearch of solid tumors with aberrant Wnt pathway activation, such as colorectal cancer .
    TNKS-2-IN-3
  • HY-119420

    Antibiotic Apoptosis Caspase JNK p38 MAPK TNF Receptor ERK NF-κB Mitochondrial Metabolism Inflammation/Immunology Cancer
    Acetoxycycloheximide is an antibiotic with antitumor activity. Acetoxycycloheximide a protein synthesis inhibitor. Acetoxycycloheximide significantly induces activation of procaspase-3 and subsequent apoptosis mediated by the Cytochrome c from mitochondria via activation of JNK pathway. Acetoxycycloheximide triggers the downregulation of cell surface TNF-R1 via the activation of ERK and p38 MAPK, thereby preventing activation of the NF-κB signaling pathway by TNF-α. Acetoxycycloheximide is much more toxic to female rats than to males. Acetoxycycloheximide can be used for inflammatory and immune diseases and cancers research .
    Acetoxycycloheximide
  • HY-144841A

    (Rac)-CFT7455

    Molecular Glues Cancer
    (Rac)-Cemsidomide ((Rac)-CFT7455) is the racemate of Cemsidomide (HY-144841) with antitumor activity . Cemsidomide is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells.
    (Rac)-Cemsidomide
  • HY-157570

    PROTACs STING Infection
    Anti-inflammatory agent 70 (N-Me-SP23) is a STING protein PROTAC degrader and inhibits the STING signaling pathway. Anti-inflammatory agent 70 has anti-inflammatory activity. (Pink: STING inhibitor (HY-47709); Black: linker (HY-W008296); Blue: CRBN Ligand (HY-W460193)) .
    Anti-inflammatory agent 70
  • HY-19542S1

    C6-Cer-d11; N-Hexanoylsphingosine-d11

    Apoptosis Isotope-Labeled Compounds Cancer
    C6 Ceramide-d11 is deuterated labeled C6 Ceramide (HY-19542). C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
    C6 Ceramide-d11
  • HY-131542

    Aldose Reductase Apoptosis Metabolic Disease
    APPA is an aldose reductase inhibitor. APPA can effectively prevent apoptosis and the symptoms of Streptozotocin (HY-13753)-induced diabetes by inhibiting the polyol pathway in rats. APPA has the potential for diabetic nephropathy (DN) research .
    APPA
  • HY-13418
    Dorsomorphin dihydrochloride
    Maximum Cited Publications
    668 Publications Verification

    Compound C dihydrochloride; BML-275 dihydrochloride

    Organoid AMPK TGF-β Receptor Autophagy Cancer
    Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
    Dorsomorphin dihydrochloride
  • HY-N0560
    Oroxylin A
    10+ Cited Publications

    Baicalein 6-methyl ether; 6-Methoxybaicalein

    HIF/HIF Prolyl-Hydroxylase Autophagy Virus Protease Cancer
    Oroxylin A is an active flavonoid compound with strong anti-cancer effects. Oroxylin A inhibits the IL-6/STAT3 pathway and NF-κB signaling, inhibits cell proliferation and induces apoptosis. Oroxylin A inhibits colitis-related carcinogenesis .
    Oroxylin A
  • HY-163461

    PARP Cancer
    4F-DDC is a novel PARP1 inhibitor with an IC50 value of 82 nM. 4F-DDC induces DNA damage and activates the cGAS–STING pathway. 4F-DDC inhibits the growth of HCC-1937-derived tumor xenografts .
    4F-DDC
  • HY-N9802

    Apoptosis Bcl-2 Family Cancer
    n-Butyl-β-D-fructofuranoside could be isolated from kangaisan. n-Butyl-β-D-fructofuranoside induces apoptosis through the mitochondrial pathway. n-Butyl-β-D-fructofuranoside can be used for cancer research .
    n-Butyl-β-D-fructofuranoside
  • HY-W011474R

    Reference Standards NF-κB Inflammation/Immunology
    Geranylgeraniol (Standard) is the analytical standard of Geranylgeraniol. This product is intended for research and analytical applications. Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model [4].
    Geranylgeraniol (Standard)
  • HY-113071

    MVA

    Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .
    Mevalonic acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: